Recruiting · registry status

Testing BHV-8000 in early Parkinson’s

Researchers are checking whether the study medicine BHV-8000 affects early Parkinson’s and whether participants can take it safely and tolerate its effects.

Testing a treatment or activity · Study reference: NCT06976268

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

Open the official registry record ↗

Who can join?

Ages 40 years to 80 years · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Key Inclusion Criteria: * Male or female participants 40 to 80 years of age, inclusive, at the time of informed consent. * Meet the diagnostic criteria for "Probable PD" as assessed on the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD as assessed by the Investigator. * Have a clinician-documented diagnosis of idiopathic PD with an onset within 2 years of the Screening Visit Key Exclusion Criteria: * Medical history indicating a Parkinsonian syndrome other than idiopathic PD, including, but not limited to, progressive supranuclear gaze palsy, multiple system atrophy, drug-induced Parkinsonism, essential tremor, or primary dystonia. * Diagnosis of clinically significant central nervous system (CNS) disease other than PD. * Participants who are current smokers (defined as smoking \[in any form, e.g., tobacco smoke, electronic cigarettes, etc.\] ) * Treatment with PD medication(s) * Any other condition(s) that may compromise participant safety, interfere with study conduct, or jeopardize the potential proper interpretation of study results, in the opinion of the investigator.

Full study name & original research details

Official study title

A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease

Short title used by the registry

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Original description

A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.

Conditions reported: Parkinson Disease

Study type: Interventional
Interventions: BHV-8000 10mg; BHV-8000 20 mg; Placebo
Phases: PHASE2; PHASE3
Sponsor: Biohaven Therapeutics Ltd.
Start date reported by registry: 2025-05-28 (actual)

Registry updated: 2026-09-28 · Status last verified by the registry submitter: 2026-09

Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Chief Medical Officer · 203-404-0410 · clinicaltrials@biohavenpharma.com

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Site-049

Birmingham, Alabama, United States

Recruiting

Site-003

Irvine, California, United States

Recruiting

Site-041

Los Angeles, California, United States

Recruiting

Site-025

Aurora, Colorado, United States

Recruiting

Site-031

Farmington, Connecticut, United States

Recruiting

Site-028

New Haven, Connecticut, United States

Recruiting

Site-038

Atlantis, Florida, United States

Recruiting

Site-017

Boca Raton, Florida, United States

Recruiting

Site-051

Maitland, Florida, United States

Recruiting

Site-027

Chicago, Illinois, United States

Recruiting

Site-029

Kansas City, Kansas, United States

Recruiting

Site-071

Boston, Massachusetts, United States

Recruiting

Site-004

Foxborough, Massachusetts, United States

Recruiting

Site-015

Farmington Hills, Michigan, United States

Recruiting

Site-044

Chesterfield, Missouri, United States

Recruiting

Site-006

Albany, New York, United States

Recruiting

Site-005

New York, New York, United States

Recruiting

Site-082

Cleveland, Ohio, United States

Recruiting

Site-091

Portland, Oregon, United States

Recruiting

Site-043

Round Rock, Texas, United States

Recruiting

Site-009

Henrico, Virginia, United States

Recruiting

Site-074

Newport News, Virginia, United States

Recruiting

Site-007

Bellevue, Washington, United States

Recruiting

Site-019

Seattle, Washington, United States

Recruiting

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.